Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
2 Top Biotech Stocks to Buy Right Now
02:00pm, Monday, 21'st Mar 2022 The Motley Fool
The global pharmaceutical industry grows in importance with each passing year. These two companies are prominent participants.
Week 12 MDA Breakout Stocks - March 2022: Short-Term Picks To Give You An Edge
04:49am, Sunday, 20'th Mar 2022 Seeking Alpha
We present 2 sample Breakout Stocks for Week 12 with better than 10% short-term upside potential and a Dow stock pick. Click here to know them.
AstraZeneca, Merck's Lynparza Cut Risk of Breast Cancer Death
05:15pm, Thursday, 17'th Mar 2022 Zacks Investment Research
Treatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.
Adagene (ADAG) Gets FDA Nod for Cancer Study on ADG126 Combo
02:42pm, Thursday, 17'th Mar 2022 Zacks Investment Research
The FDA grants clearance to Adagene (ADAG) to begin clinical studies on its anti-CTLA-4 mAb, ADG126 in combination with pembrolizumab to treat advanced/metastatic solid tumors.
Here's Why Merck (MRK) is a Strong Value Stock
02:00pm, Thursday, 17'th Mar 2022 Zacks Investment Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Moderna (MRNA) Up More Than 30% in 10 Days: What Lies Ahead?
01:55pm, Thursday, 17'th Mar 2022 Zacks Investment Research
Moderna's (MRNA) shares are rising presumably in anticipation of rising demand for its COVID-19 vaccine amid authorization for younger population and the fear of another global infection wave.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
09:45pm, Wednesday, 16'th Mar 2022 Zacks Investment Research
Merck (MRK) closed the most recent trading day at $78.12, moving -0.66% from the previous trading session.
AstraZeneca and Merck''s Lynparza shows survival benefit in early breast cancer
09:00pm, Wednesday, 16'th Mar 2022 Seeking Alpha
Results from a phase 3 trial demonstrated an improvement in overall survival compared to placebo in patients taking AstraZeneca (AZN) and Mercks Lynparza for breast cancer.
Iovance (IOVA) to Start Clinical Studies for TIL Therapy
03:57pm, Wednesday, 16'th Mar 2022 Zacks Investment Research
Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.
AbbVie (ABBV) Inks Deal to Develop COVID Antiviral Treatment
03:41pm, Wednesday, 16'th Mar 2022 Zacks Investment Research
AbbVie (ABBV) joins Scripps Research in the latter's SARS-CoV-2 research program to accelerate the development of new antiviral therapies for COVID-19.
Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
02:00pm, Wednesday, 16'th Mar 2022 Benzinga
The FDA has cleared Adagene Inc''s (NASDAQ: ADAG ) Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with Merck & Co Inc''s (NYSE: MRK ) Keytruda (pembrolizumab). The global trial (ADG126-P001 / KEYNOTE-C98) will evaluate patients with advanced/metastatic solid … Full story available on Benzinga.com
Merck (MRK) Stops Keytruda-Lynparza Combo Prostate Cancer Study
01:00pm, Wednesday, 16'th Mar 2022 Zacks Investment Research
Merck (MRK) decides to discontinue a late-stage prostate cancer study evaluating Keytruda in combination with AstraZeneca's Lynparza, following its failure to demonstrate a benefit in overall survival
Adagene, Merck gets FDA clearance to advance ADG126/Keytruda combo in solid tumor study
12:11pm, Wednesday, 16'th Mar 2022 Seeking Alpha
Adagene (ADAG) said it received FDA clearance to proceed with a phase 1b/2 trial of ADG126, in combination with the Merck''s (MRK) Keytruda (pembrolizumab) in solid tumors.The global…
Sewage samples signal possible increase in U.S. COVID cases in some places, even though overall cases are falling
10:11am, Wednesday, 16'th Mar 2022 MarketWatch
A jump in coronavirus rates measured at wastewater sampling sites monitored by the Centers for Disease Control and Prevention may be signaling a coming increase in COVID-19 cases in parts of the U.S.,
Nektar (NKTR) Plunges on Bempeg's Melanoma Study Failure
02:38pm, Tuesday, 15'th Mar 2022 Zacks Investment Research
Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.
